drugset
drugset / Trial / NCT03520517

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517 ↗

Phase 1 Completed 22 enrolled Biohaven Pharmaceuticals, Inc. Cognitive Research Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 1, open-label study of BHV-0223 in ALS.

Timeline

Start
2018-02-02
Primary completion
2018-10-08
Completion
2018-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 40 mg Other

Indications

amyotrophic lateral sclerosis